Core Viewpoint - Xianruida Medical-B (06669) experienced a significant stock price increase of over 13% following the release of its interim results, indicating positive market sentiment towards the company's performance and future prospects [1] Financial Performance - The company reported a revenue of 351 million RMB for the first half of the year, representing a year-on-year increase of 20.1% [1] - Net profit for the same period was 88.577 million RMB, showing a substantial year-on-year growth of 121.7% [1] Regulatory Approval - Xianruida Medical received registration approval from the National Medical Products Administration of China for its peripheral controllable mechanical release fiber spring ring, which is intended for use in treating peripheral vascular aneurysms, arteriovenous malformations, and arteriovenous fistulas [1] - The company plans to initiate marketing activities in China for this product in a timely manner [1] Strategic Developments - In December 2022, Boston Scientific initiated a takeover bid for Xianruida Medical, offering 20 HKD per share for up to 65% of the company's majority stake, with an estimated transaction value of approximately 523 million USD [1] - In July 2023, both parties signed a cooperation framework agreement and service framework agreement to collaborate on global commercialization, manufacturing services, and product development [1]
港股异动 | 先瑞达医疗-B(06669)绩后涨超13% 上半年收入增超20% 纯利同比增长121%